Cyclooxygenase-2 is an obligatory factor in methamphetamine-induced neurotoxicity

Journal of Pharmacology and Experimental Therapeutics

Volumn 313, Issue 2, 2005, Pages 870-876

  Thomas, David M ^a,b   Kuhn, Donald M ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; CCAAT ENHANCER BINDING PROTEIN; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYCLOOXYGENASE 3 INHIBITOR; DOPAMINE; KETOPROFEN; METHAMPHETAMINE; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PEROXIDASE; PHENAZONE; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE INHIBITOR; QUINONE DERIVATIVE; REACTIVE OXYGEN METABOLITE; ROFECOXIB; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; ENZYME ACTIVITY; ENZYME INDUCTION; FEMALE; GENE EXPRESSION; GENE MUTATION; KNOCKOUT MOUSE; MOUSE; NERVE CELL LESION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; PROTEIN MICROARRAY; WILD TYPE;

ANIMALS; CORPUS STRIATUM; CYCLOOXYGENASE 2; DOPAMINE; FEMALE; METHAMPHETAMINE; MICE; MICE, INBRED C57BL; NEURONS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;

EID: 18044384646     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.104.080242     Document Type: Article

References (42)

1. Ali SF and Itzhak Y (1998) Effects of 7-nitroindazole, an NOS inhibitor on methamphetamine-induced dopaminergic and serotonergic neurotoxicity in mice. Ann NY Acad Sci 844:122-130.
2. Asanuma M, Tsuji T, Miyazaki I, Miyoshi K, and Ogawa N (2003) Methamphetamine-induced neurotoxicity in mouse brain is attenuated by ketoprofen, a non-steroidal anti-inflammatory drug. Neurosci Lett 352:13-16.
3. Ayoub SS, Botting RM, Goorha S, Colville-Nash PR, Willoughby DA, and Ballou LR (2004) Acetaminophen-induced hypothermia in mice is mediated by a prostaglandin endoperoxide synthase 1 gene-derived protein. Proc Natl Acad Sci USA 101:11165-11169.
4. Baucum AJ 2nd, Rau KS, Riddle EL, Hanson GR, and Fleckenstein AE (2004) Methamphetamine increases dopamine transporter higher molecular weight complex formation via a dopamine- and hyperthermia-associated mechanism. J Neurosci 24:3436-3443.
5. Bowyer JF, Davies DL, Schmued L, Broening HW, Newport GD, Slikker W Jr, and Holson RR (1994) Further studies of the role of hyperthermia in methamphetamine neurotoxicity. J Pharmacol Exp Ther 268:1571-1580.
6. Bowyer JF, Tank AW, Newport GD, Slikker W Jr, Ali SF, and Holson RR (1992) The influence of environmental temperature on the transient effects of methamphetamine on dopamine levels and dopamine release in rat striatum. J Pharmacol Exp Ther 260:817-824.
7. Burrows KB, Gudelsky G, and Yamamoto BK (2000) Rapid and transient inhibition of mitochondrial function following methamphetamine or 3,4-methylenedioxymethamphetamine administration. Eur J Pharmacol 398:11-18.
8. Cadet JL, Jayanthi S, and Deng X (2003) Speed kills: cellular and molecular bases of methamphetamine-induced nerve terminal degeneration and neuronal apoptosis. FASEB J 17:1775-1788.
9. Caivano M, Gorgoni B, Cohen P, and Poli V (2001) The induction of cyclooxygenase-2 mRNA in macrophages is biphasic and requires both CCAAT enhancer-binding protein beta (C/EBP beta) and C/EBP delta transcription factors. J Biol Chem 276:48693-48701.
10. Chandrasekharan NV, Dai H, Roos KL, Evanson NK, Tomsik J, Elton TS, and Simmons DL (2002) COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure and expression. Proc Natl Acad Sci USA 99:13926-13931.
11. Cortes-Canteli M, Wagner M, Ansorge W, and Perez-Castillo A (2004) Microarray analysis supports a role for ccaat/enhancer-binding protein-beta in brain injury. J Biol Chem 279:14409-14417.
12. Darvesh AS and Gudelsky GA (2004) The relationship between hyperthermia and glycogenolysis in 3,4-methylenedioxymethamphetamine-induced serotonin depletion in rats. Neurotoxicol Teratol 26:571-577.
13. Davidson C, Gow AJ, Lee TH, and Ellinwood EH (2001) Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Res Brain Res Rev 36:1-22.
14. Feng ZH, Wang TG, Li DD, Fung P, Wilson BC, Liu B, Ali SF, Langenbach R, and Hong JS (2002) Cyclooxygenase-2-deficient mice are resistant to 1-methyl-4-phenyl1,2,3,6-tetrahydropyridine-induced damage of dopaminergic neurons in the substantia nigra. Neurosci Lett 329:354-358.
15. Hastings TG (1995) Enzymatic oxidation of dopamine: the role of prostaglandin H synthase. J Neurochem 64:919-924.
16. Haughey HM, Fleckenstein AE, and Hanson GR (1999) Differential regional effects of methamphetamine on the activities of tryptophan and tyrosine hydroxylase. J Neurochem 72:661-668.
17. Hurley SD, Olschowka JA, and O'Banion MK (2002) Cyclooxygenase inhibition as a strategy to ameliorate brain injury. J Neurotrauma 19:1-15.
18. Iadecola C, Niwa K, Nogawa S, Zhao X, Nagayama M, Araki E, Morham S, and Ross ME (2001) Reduced susceptibility to ischemic brain injury and N-methyl-D-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice. Proc Natl Acad Sci USA 98:1294-1299.
19. Kita T, Shimada K, Mastunari Y, Wagner GC, Kubo K, and Nakashima T (2000) Methamphetamine-induced striatal dopamine neurotoxicity and cyclooxygenase-2 protein expression in BALB/c mice. Neuropharmacology 39:399-406.
20. Kita T, Wagner GC, and Nakashima T (2003) Current research on methamphetamine-induced neurotoxicity: animal models of monoamine disruption. J Pharmacol Sci 92:178-195.
21. Kuhn DM and Arthur R Jr (1998) Dopamine inactivates tryptophan hydroxylase and forms a redox-cycling quinoprotein: possible endogenous toxin to serotonin neurons. J Neurosci 18:7111-7117.
22. Kuhn DM, Arthur RE Jr, Thomas DM, and Elferink LA (1999) Tyrosine hydroxylase is inactivated by catechol-quinones and converted to a redox-cycling quinoprotein: possible relevance to Parkinson's disease. J Neurochem 73:1309-1317.
23. LaVoie MJ, Card JP, and Hastings TG (2004) Microglial activation precedes dopamine terminal pathology in methamphetamine-induced neurotoxicity. Exp Neurol 187:47-57.
24. LaVoie MJ and Hastings TG (1999) Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: evidence against a role for extracellular dopamine. J Neurosci 19:1484-1491.
25. Le W, Rowe D, Xie W, Ortiz I, He Y, and Appel SH (2001) Microglial activation and dopaminergic cell injury: an in vitro model relevant to Parkinson's disease. J Neurosci 21:8447-8455.
26. Li S, Ballou LR, Morham SG, and Blatteis CM (2001) Cyclooxygenase-2 mediates the febrile response of mice to interleukin-1beta. Brain Res 910:163-173.
27. Maharaj DS, Saravanan KS, Maharaj H, Mohanakumar KP, and Daya S (2004) Acetaminophen and aspirin inhibit superoxide anion generation and lipid peroxidation and protect against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats. Neurochem Int 44:355-360.
28. Metzger RR, Haughey HM, Wilkins DG, Gibb JW, Hanson GR, and Fleckenstein AE (2000) Methamphetamine-induced rapid decrease in dopamine transporter function: role of dopamine and hyperthermia. J Pharmacol Exp Ther 295:1077-1085.
29. Miller DB and O'Callaghan JP (1994) Environment-, drug- and stress-induced alterations in body temperature affect the neurotoxicity of substituted amphetamines in the C57BL/6J mouse. J Pharmacol Exp Ther 270:752-760.
30. Mirjany M, Ho L, and Pasinetti GM (2002) Role of cyclooxygenase-2 in neuronal cell cycle activity and glutamate-mediated excitotoxicity. J Pharmacol Exp Ther 301:494-500.
31. Orio L, O'Shea E, Sanchez V, Pradillo JM, Escobedo I, Camarero J, Moro MA, Green AR, and Colado MI (2004) 3,4-Methylenedioxymethamphetamine increases interleukin-1beta levels and activates microglia in rat brain: studies on the relationship with acute hyperthermia and 5-HT depletion. J Neurochem 89:1445-1453.
32. Paz MA, Fluckiger R, Boak A, Kagan HM, and Gallop PM (1991) Specific detection of quinoproteins by redox-cycling staining. J Biol Chem 266:689-692.
33. Sairam K, Saravanan KS, Banerjee R, and Mohanakumar KP (2003) Non-steroidal anti-inflammatory drug sodium salicylate, but not diclofenac or celecoxib, protects against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats. Brain Res 966:245-252.
34. Simmons DL, Botting RM, and Hla T (2004) Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev 56:387-437.
35. Smith WL, DeWitt DL, and Garavito KM (2000) Cyclooxygenases: structural, cellular and molecular biology. Annu Rev Biochem 69:145-182.
36. Sulzer D, Chen TK, Lau YY, Kristensen H, Rayport S, and Ewing A (1995) Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J Neurosci 15:4102-4108.
37. Teismann P and Ferger B (2001) Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease. Synapse 39:167-174.
38. Teismann P, Tieu K, Choi DK, Wu DC, Naini A, Hunot S, Vila M, Jackson-Lewis V, and Przedborski S (2003) Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc Natl Acad Sci USA 100:5473-5478.
39. Thomas DM, Francescutti-Verbeem DM, Liu X, and Kuhn DM (2004a) Identification of differentially regulated transcripts in mouse striatum following methamphetamine treatment-an oligonucleotide microarray approach. J Neurochem 88:380-393.
40. Thomas DM, Walker PD, Benjamins JA, Geddes TJ, and Kuhn DM (2004b) Methamphetamine neurotoxicity in dopamine nerve endings of the striatum is associated with microglial activation. J Pharmacol Exp Ther 311:1-7.
41. Walton M, Saura J, Young D, MacGibbon G, Hansen W, Lawlor P, Sirimanne E, Gluckman P, and Dragunow M (1998) CCAAT-enhancer binding protein alpha is expressed in activated microglial cells after brain injury. Brain Res Mol Brain Res 61:11-22.
42. Whitehead RE, Ferrer JV, Javitch JA, and Justice JB (2001) Reaction of oxidized dopamine with endogenous cysteine residues in the human dopamine transporter. J Neurochem 76:1242-1251.